11.21.2017
Prevent & Delay
$550,000.00
48 months
Engineering antigen-specific regulatory T cells for use in type 1 diabetes
Funds support a work into a preclinical proof-of-principle for an engineered targeted Treg cell therapy to treat type 1 diabetes.